Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
Polaryx Therapeutics Inc. (NASDAQ:PLYX) shares are up on Tuesday as the company has made significant strides in advancing its clinical programs.
The positive movement follows the announcement that Polaryx has selected a contract research organization for its SOTERIA Phase 2 basket trial, which aims to evaluate its lead candidate, PLX-200, across multiple lysosomal storage disorders.
The SOTERIA trial represents a flexible and resource-efficient mechanism for the clinical development of PLX-200.
Polaryx’s selection of a leading contract research organization marks a pivotal milestone as it prepares to initiate the SOTERIA trial in the first half of 2026. The trial is designed to assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders, with the company having received a safe to proceed letter from the FDA in October 2025.
The SOTERIA trial will incorporate analyses comparing natural history data as a control arm to the treated arm of PLX-200, which is an orally available compound derived from gemfibrozil. This trial is expected to gather crucial data that will inform the future clinical development pathway for PLX-200, potentially leading to conditional marketing authorization if compelling clinical activity is demonstrated.
PLYX Price Action: Polaryx Therapeutics shares were up 46.06% at $3.52 at the time of publication on Tuesday. The stock is trading near its 52-week low of $2.20.
Photo: jittawit21/Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Litecoin climbs 3.3% to $56.11, faces key resistance at $58.55
Bernstein: ASIC CPU Brings Additional Incremental Demand, Raises Target Price for TSMC (TSM.US) to $600
Bernstein stated that Amazon and Google’s self-developed ASIC CPUs are driving demand for TSMC, with CPU revenue expected to double to $50 billion by 2028. The target price has been raised to $600.
AI investment continues to increase, cost control pressure rises, Google (GOOGL.US) expands scope of voluntary employee buyout program
Facing massive spending in the artificial intelligence (AI) sector, Google is seeking to control rising costs and has expanded its employee buyout program to several countries this year.
CrowdStrike (CRWD.US) spends nearly $500 million to secure a position in AI security, Morgan Stanley turns bullish immediately: $308 bull market target price is closer
Morgan Stanley maintains its "Overweight" rating on CrowdStrike, with a base case price target of $254, and has further increased confidence in the bull case price target of $308.
Crypto prices
More
